Bristol Myers Squibb (NYSE: BMY) and Johnson & Johnson (NYSE: JNJ) compete against each other in the marketplace every day. In this Motley Fool Live video recorded on Nov. 16, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss the prospects for this experimental drug. Keith Speights: Bristol Myers Squibb and Johnson & Johnson compete head-to-head in the blood thinner market.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting